Recruiting

Genex with Gentamicin

Sponsor:

Biocomposites Ltd

Code:

NCT07270380

Conditions

Osteomyelitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

genex with gentamicin (genex G)

Study Details

Brief summary:

The purpose of this trial is to determine if genex with gentamicin (genex G) an antibiotic loaded bone void filler, works to treat and is a safe option as part of the surgical treatment of osteomyelitis in the extremities.

Conditions

Osteomyelitis

Study ID

NCT07270380

Start date

Jun, 2026

Status verified date

Jul, 2026

Completion date

Oct, 2028

Anticipated

Primary completion date

Oct, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patient with osteomyelitis of the extremities, who have failed antibiotic therapy and are requiring surgical intervention (unresolved osteomyelitis), Cierny-Mader classification of osteomyelitis grades I-IV. Patients presenting with Cierny-Mader grades I-II will be required to have a defect created as part of debridement surgery
2. Patients at least 18 years of age \*1
3. Patient willing and able to provide written informed consent
4. Patient geographically stable and able to comply with the required follow-up visits and testing schedule as assessed by the investigator
5. Ability to achieve adequate surgical soft tissue coverage of the wound (primary tissue closure or surgical reconstruction including local and free soft tissue transfer)

  • 1 Patients between 18 and 22 years of age require confirmation of skeletal maturity as validated by radiographs of the bone to be treated.

Exclusion Criteria:

1. Patients diagnosed with acute osteomyelitis
2. Patients with Cierny-Mader grades I-II who are unable to have a defect created during debridement surgery
3. Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/dL (309umol/L) or being treated with dialysis
4. Participants with a terminal or palliative diagnosis (e.g. terminal cancer diagnosis) deemed to have less than 1 year life expectancy by their health care team
5. Uncontrolled diabetes mellitus (hemoglobin A1c levels >10%)
6. Pre-existing calcium metabolism disorder
7. Women who are pregnant or breastfeeding or planning on becoming pregnant during the study (a pregnancy test will be done in women of childbearing potential at screening and on the day of surgery)
8. History of hypersensitivity or contraindication to the investigational device or any of its ingredients (calcium phosphate, β-tricalcium phosphate, and aminoglycoside antibiotics)
9. Participation in an investigational drug/device study (within the last 60 days) or prior enrolment to the ADOPT GG study
10. Clinically significant or unstable medical or surgical condition that in the investigators opinion may preclude safe and complete study participation (for example patients medically unfit for surgery, general anesthesia, or any risk of significant blood loss resulting in significant risk to loss of life)
11. Current untreated malignant neoplasm(s), or current treatment with radiation therapy or chemotherapy
12. Current or recent history (within last 2 years) of active substance abuse (e.g. recreational drugs, narcotics, or alcohol) that meets DSM-5 severe criteria
13. Current user of any products containing nicotine
14. Currently incarcerated

Study Design

Enrollment

139 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Single Arm

Participants will receive genex with Gentamicin, an antibiotic loaded bone void filler that supports bone healing, as part of the surgical treatment of osteomyelitis of the extremities.

Interventions

genex with gentamicin (genex G)

genex with gentamicin will be implanted during debridement surgery

Primary outcome measure

  • No further requirement for antibiotic treatment due to persisting symptoms of infection at the index site (i.e., additional antibiotics prescribed following completion of the initial systemic antibiotics prescribed post surgery. [ Time Frame: Month 12 ]
  • No further surgical interventions required due to infection at the index site. [ Time Frame: Month 12 ]
  • No recurrence of sinus formation at the index site. [ Time Frame: Month 12 ]

Central Contacts and Locations

Locations

North Park Podiatry

Recruiting

San Diego, California, United States, 92104

Contacts

Trent Brookshier, DPM

trentbrookshier@gmail.com

Principal Investigator:

Trent Brookshier, DPM

OrthoIndy

Recruiting

Indianapolis, Indiana, United States, 46278

Contacts

Kimberly Fitzpatrick

kifitzpatrick@orthoindy.com

Melanie Glover

mglover@orthoindy.com

Principal Investigator:

Sandeep Soin, MD

Sinai Hospital Baltimore

Recruiting

Baltimore, Maryland, United States, 21215

Contacts

Principal Investigator:

Janet Conway, MD

Curalta Clinical Trials

Recruiting

Oradell, New Jersey, United States, 07649

Contacts

Radhika Gajera

rgajera@curalta.com

Harrison Miller

hmiller@curalta.com

Principal Investigator:

Vincent Giacalone, DPM

More Information

Sponsor

Biocomposites Ltd

Last update posted

Jul 28, 2026

Last verified

Jul, 2026

Keywords

  • Single Arm
  • Historical Control
  • Pivotal Device Study
  • Bone Void Filler
  • Gentamicin
  • Systemic Antibiotics
  • genex

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Biocomposites Ltd on 2026-07-28.